Picture of Taisho Pharmaceutical Holdings Co logo

4581 — Taisho Pharmaceutical Holdings Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Activist fund Oasis says it may take legal action over Taisho's management buyout

By Makiko Yamazaki
       TOKYO, March 8 (Reuters) - Activist fund Oasis
Management is considering legal action over Taisho
Pharmaceutical's  4581.T  $5 billion management buyout - Japan's
largest to date - arguing that it was deeply unfair to minority
shareholders.
    Taisho's founding family gained 73% of the company in a
tender offer in January for 8,620 yen per share - a 55% premium
to Taisho's share price before the offer was announced but which
was still below book value.
    Seth Fischer, Oasis's founder and chief investment officer,
told Reuters that the Hong Kong-based fund could ask a court to
determine the fair value of Taisho's stock in a so-called
appraisal process. Or it could sue Taisho's board of directors
for breach of duty.
        Oasis has previously gone to court to seek higher prices
for its shares in buyouts as it did when Japanese trading house
Itochu  8001.T  acquired convenience store operator FamilyMart
in 2020. The court decided in favour of Oasis. FamilyMart has
appealed the decision as has Oasis which is contesting how the
share price was calculated.
    Fischer said there had been "an extreme conflict of
interest" in the Taisho deal given that the founding family had
owned more than a third of the company prior to the buyout.
    Taisho is holding a shareholder vote on March 18 on a
reverse stock split that would consolidate Taisho's shares - a
vote it is sure to win as it commands more than the two-thirds
of the vote needed to secure approval. It would then be delisted
in April.
    Taisho's board has said the transaction is fair to minority
shareholders.
    Fischer called for Japan to adopt stronger protections for
minority shareholders in management buyouts.
    He said that when considering deals, companies should have a
truly independent special committee, seek an independent
fairness opinion, solicit alternative offers and use so-called
majority-of-the-minority votes where a controlling shareholder
is excluded.
    "I'm not against MBOs in general. I want MBOs to be fair. I
want the buyers to be fair," he said.
    Oasis has not disclosed its stake in Taisho but has said it
has been a shareholder for a long time.
    Amid increasing pressure from regulators and shareholders to
improve corporate returns, Japan has seen a surge in MBOs. It
had 29 MBOs last year, according to LSEG data as of Dec 6.

    

 (Reporting by Makiko Yamazaki; Editing by Edwina Gibbs)
 ((Makiko.Yamazaki@thomsonreuters.com; +81-3-4563-2805;))

Recent news on Taisho Pharmaceutical Holdings Co

See all news